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Off-label drug use
The off-label use of pharmaceutical products is widely 
practised by medical practitioners. The term ‘off-label’ means 
that the medicine is used in another way or for an indication 
other than those specified in the conditions of registration of 
the medicine and as reflected on its labelling. Two papers1,2 
and an accompanying editorial3 in this journal address clinical, 
legal and ethical implications arising from the use of such 
products.
In one example dinoprostone is registered for use in South 
Africa for the induction of labour, yet is commonly used in 
South Africa for the emergency maintenance of ductal patency 
in newborn babies.1 The temporary lack of dinoprostone due 
to logistical problems at the pharmaceutical company led to 
difficulties in managing a small infant with pulmonary atresia. 
The authors plead for information to be provided concerning 
the shortage of any drug, including those for off-label use, in 
order to plan effectively.
The other paper2 considers the implications of the intra-
ocular (off-label) use of bevacizumab (Avastin), which 
is registered for treating metastatic colorectal and breast 
cancer. Avastin blocks vascular endothelial growth factor 
(VEGF), thus preventing further growth of blood vessels. 
It is effective in the treatment of age-related ‘wet’ macular 
degeneration. Its off-label use has been controversial mainly 
because two other anti-VEGF drugs are on the market, but at 
very much higher prices that would put them out of reach of 
poorer patients. The South African Vitreoretinal Society has 
developed protocols endorsed by the Ophthalmological Society 
for administering Avastin and other intra-ocular medication 
intravitreally.
In the guidelines on thromboembolism published in this 
journal4 it is noted that there are no drugs registered for 
prophylaxis in pregnancy and that their recommendations are 
also off-label.
The off-label use of any medication carries a higher risk for 
the patient and the medical practitioner than its registered 
use. From a legal/ethical point of view the off-label use of 
medication represents a delicate balance between the statutory 
regulation of medication to safeguard patients against unsafe 
and ineffective medications, and the prerogative of a physician 
to prescribe medication that, in his or her opinion, will benefit 
the patient. 
Venous thromboembolism: 
Prophylactic and therapeutic guideline 
In the absence of anticoagulation, the risk of deep-vein 
thrombosis (DVT) in medically ill patients is comparable to 
that observed in moderate-risk surgical patients: 10 - 20%. 
Pulmonary embolism is the most common preventable cause 
of death in hospital patients, accounting for 10% of all hospital 
deaths. Pharmacological prophylactic anticoagulation in many 
countries, including South Africa, is under-prescribed resulting 
in unacceptable morbidity and mortality in substantial 
numbers of patients. A concise, practical guideline for thrombo-
prophylaxis and treatment in medical and surgical patients, 
endorsed by several major specialist societies, has therefore 
been produced for South African conditions.4
Prophylaxis is not required for patients who are mobile. 
In patients at high risk of bleeding, the use of mechanical 
prophylaxis such as graduated compression stockings or 
intermittent pneumatic compression devices should be 
considered as an alternative if the thrombosis risk is high. 
In surgical patients both patient-related and procedure-
related factors should be considered when assessing an 
individual’s risk of developing venous thomboembolism. 
Details for anticoagulation therapy are provided including the 
use of low-molecular-weight heparin and warfarin as well as 
the management of patients with bleeding.
Predicting fetal weight in labour at 
term
Clinicians frequently estimate fetal weight when examining 
women in labour at term. This may help in predicting 
cephalopelvic disproportion when labour progress is poor 
or give early warning of possible shoulder dystocia. Eckart 
Buchmann and Karabo Tlale report on their derivation and 
validation of a simple formula for birth weight based on 
symphysis-fundal height (SFH) measurement during labour 
and determining a useful SFH cut-off value for prediction of 
birth weight.5 They conclude that this formula may be useful 
for intrapartum use in term pregnancies.
Aminoglycoside-induced hearing loss
South Africa’s TB epidemic and the threat to TB control posed 
by the emergence of multidrug-resistant and extensively drug- 
resistant TB strains put patients at risk of hearing loss because 
of the necessity of prolonged chemotherapy. Drug-related 
adverse effects of aminoglycosides include ototoxicity that is 
permanent. In their editorial on the topic,6 Bardien, De Jong 
and colleagues explore ways of dealing with this potential 
problem, including the proposal to introduce genetic testing for 
patients at risk of aminoglycoside-induced hearing loss.
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